MX355830B - Modulacion de activacion de macrofagos. - Google Patents
Modulacion de activacion de macrofagos.Info
- Publication number
- MX355830B MX355830B MX2014004682A MX2014004682A MX355830B MX 355830 B MX355830 B MX 355830B MX 2014004682 A MX2014004682 A MX 2014004682A MX 2014004682 A MX2014004682 A MX 2014004682A MX 355830 B MX355830 B MX 355830B
- Authority
- MX
- Mexico
- Prior art keywords
- directed
- csf
- bind
- antibody
- macrophage activation
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title abstract 5
- 230000004913 activation Effects 0.000 title abstract 4
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000010287 polarization Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a promover la respuesta inmune tipo M1 (polarización de macrófago M1) al administrar un compuesto que modula la activación de macrófago. La invención es dirige al uso de un anticuerpo capaz de unirse a CSF-1R para modular la activación de macrófagos. La invención también se dirige a métodos para evaluar la eficacia de dosis de un anticuerpo capaz de unirse a CSF-1R en un paciente al valorar la activación in vivo o in vitro de macrófagos. La invención se dirige adicionalmente a la prueba de compañero post-tratamiento y ensayos para valorar el efecto de un anticuerpo capaz de unirse a CSF-1R en un sujeto siendo tratado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306368 | 2011-10-21 | ||
| PCT/EP2012/070805 WO2013057281A2 (en) | 2011-10-21 | 2012-10-19 | Modulation of macrophage activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014004682A MX2014004682A (es) | 2014-10-17 |
| MX355830B true MX355830B (es) | 2018-05-02 |
Family
ID=47178588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004682A MX355830B (es) | 2011-10-21 | 2012-10-19 | Modulacion de activacion de macrofagos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9139652B2 (es) |
| EP (1) | EP2768862A2 (es) |
| JP (1) | JP6005751B2 (es) |
| KR (1) | KR102061358B1 (es) |
| CN (1) | CN103958546B (es) |
| AU (1) | AU2012324847B2 (es) |
| BR (1) | BR112014008540A2 (es) |
| CA (1) | CA2851771C (es) |
| HK (1) | HK1200032A1 (es) |
| IL (1) | IL231055A (es) |
| MX (1) | MX355830B (es) |
| RU (1) | RU2639553C2 (es) |
| SG (1) | SG11201401639QA (es) |
| WO (1) | WO2013057281A2 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| SI2949670T1 (sl) | 2009-12-10 | 2019-05-31 | F. Hoffmann-La Roche Ag | Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba |
| RS58211B1 (sr) | 2010-05-04 | 2019-03-29 | Five Prime Therapeutics Inc | Antitela koja vezuju csf1r |
| KR20140113683A (ko) | 2011-12-15 | 2014-09-24 | 에프. 호프만-라 로슈 아게 | 인간 csf-1r에 대한 항체 및 이의 용도 |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| RU2718751C2 (ru) | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r) |
| EP2938635A1 (en) * | 2012-11-09 | 2015-11-04 | Transgene SA | Modulation of monocytes, or precursors thereof, differentiation |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EP3157957A1 (en) | 2014-06-23 | 2017-04-26 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SMT202100164T1 (it) | 2014-10-29 | 2021-05-07 | Bristol Myers Squibb Co | Terapia di combinazione per il cancro |
| JP6797801B2 (ja) | 2014-12-22 | 2020-12-09 | ファイヴ プライム セラピューティクス インク | Ｐｖｎｓを治療するための抗ｃｓｆ１ｒ抗体 |
| CA2980460A1 (en) | 2015-04-13 | 2016-10-20 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| BR112018076281A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo |
| CN106267174A (zh) * | 2016-08-04 | 2017-01-04 | 大连大学 | M1巨噬细胞肿瘤疫苗的制备方法 |
| WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| WO2018195263A1 (en) * | 2017-04-20 | 2018-10-25 | The Board Of Regents Of The University Of Texas System | Methods for the treatment of cancer metastasis |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| KR101960410B1 (ko) | 2017-07-08 | 2019-03-20 | 허갑용 | 염화코발트로 유도된 저산소 환경을 이용한 융합효율이 높은 전이암 하이브리드 세포의 제조방법 |
| WO2019014511A2 (en) * | 2017-07-14 | 2019-01-17 | Minzhen Xu | METHOD FOR INDUCING AN IMMUNE RESPONSE DOMINATED BY M1 AND PHARMACEUTICAL COMPOSITIONS |
| GB201713975D0 (en) * | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| BR112020004879A2 (pt) | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
| TW202023629A (zh) * | 2018-06-29 | 2020-07-01 | 美商維西歐製藥公司 | 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途 |
| KR102165583B1 (ko) * | 2018-11-23 | 2020-10-14 | 농업회사법인 주식회사 나무바이오 | 전방향 야생동물 퇴치기 |
| CN109609452A (zh) * | 2018-12-27 | 2019-04-12 | 青岛麦迪赛斯生物科技有限公司 | 一种高效的巨噬细胞体外制备方法 |
| US11590236B2 (en) | 2019-03-27 | 2023-02-28 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for altering macrophage phenotype |
| US11859169B2 (en) | 2020-02-28 | 2024-01-02 | Korea University Research And Business Foundation | Nano-ligand for promoting cell adhesion and regeneration of macrophages and method of promoting cell adhesion and regeneration of macrophages by using the same |
| KR102300182B1 (ko) | 2020-02-28 | 2021-09-10 | 고려대학교 산학협력단 | 줄기세포의 세포 부착 및 분화 촉진용 나노리간드 및 이를 이용한 줄기세포의 세포 부착 및 분화 촉진 방법 |
| KR20220152258A (ko) | 2020-03-05 | 2022-11-15 | 쇼오트 아게 | 유리의 용융 방법 및 장치 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591355A1 (ru) | 2007-08-21 | 2016-04-29 | Амген Инк. | АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА |
| US8470977B2 (en) * | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| MX2010009894A (es) * | 2008-03-14 | 2011-02-22 | Transgene Sa | Anticuerpo contra csf-1r. |
| SI2949670T1 (sl) * | 2009-12-10 | 2019-05-31 | F. Hoffmann-La Roche Ag | Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba |
-
2012
- 2012-10-19 MX MX2014004682A patent/MX355830B/es active IP Right Grant
- 2012-10-19 SG SG11201401639QA patent/SG11201401639QA/en unknown
- 2012-10-19 WO PCT/EP2012/070805 patent/WO2013057281A2/en active Application Filing
- 2012-10-19 RU RU2014120212A patent/RU2639553C2/ru not_active IP Right Cessation
- 2012-10-19 JP JP2014536263A patent/JP6005751B2/ja not_active Expired - Fee Related
- 2012-10-19 BR BR112014008540-4A patent/BR112014008540A2/pt not_active Application Discontinuation
- 2012-10-19 CN CN201280051686.6A patent/CN103958546B/zh not_active Expired - Fee Related
- 2012-10-19 CA CA2851771A patent/CA2851771C/en not_active Expired - Fee Related
- 2012-10-19 AU AU2012324847A patent/AU2012324847B2/en not_active Ceased
- 2012-10-19 US US14/352,262 patent/US9139652B2/en not_active Expired - Fee Related
- 2012-10-19 EP EP12786861.0A patent/EP2768862A2/en not_active Ceased
- 2012-10-19 KR KR1020147010224A patent/KR102061358B1/ko active IP Right Grant
-
2014
- 2014-02-20 IL IL231055A patent/IL231055A/en active IP Right Grant
-
2015
- 2015-01-15 HK HK15100462.2A patent/HK1200032A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2639553C2 (ru) | 2017-12-21 |
| WO2013057281A3 (en) | 2013-06-13 |
| AU2012324847A1 (en) | 2014-03-06 |
| CA2851771C (en) | 2018-09-11 |
| KR102061358B1 (ko) | 2019-12-31 |
| MX2014004682A (es) | 2014-10-17 |
| AU2012324847B2 (en) | 2017-01-12 |
| CA2851771A1 (en) | 2013-04-25 |
| KR20140084043A (ko) | 2014-07-04 |
| RU2014120212A (ru) | 2015-11-27 |
| CN103958546A (zh) | 2014-07-30 |
| US9139652B2 (en) | 2015-09-22 |
| BR112014008540A2 (pt) | 2020-12-01 |
| JP6005751B2 (ja) | 2016-10-12 |
| NZ621911A (en) | 2015-09-25 |
| SG11201401639QA (en) | 2014-05-29 |
| US20140255417A1 (en) | 2014-09-11 |
| WO2013057281A2 (en) | 2013-04-25 |
| EP2768862A2 (en) | 2014-08-27 |
| JP2014532618A (ja) | 2014-12-08 |
| IL231055A (en) | 2017-07-31 |
| CN103958546B (zh) | 2017-10-27 |
| IL231055A0 (en) | 2014-03-31 |
| HK1200032A1 (en) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355830B (es) | Modulacion de activacion de macrofagos. | |
| CY1124428T1 (el) | Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1 | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| PH12014502399B1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| CY1119590T1 (el) | Ρυθμιστες dll3 και μεθοδοι χρησης | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| PH12016500482A1 (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
| MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
| EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| NZ705008A (en) | Novel modulators and methods of use | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| UA110103C2 (uk) | Модифікований туберкульозний антиген | |
| MX2015011772A (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| TR201904980T4 (tr) | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. | |
| MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
| CY1115463T1 (el) | Βιολογικα υλικα και χρησεις αυτων | |
| FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
| MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| RU2012107975A (ru) | Способ ранней диагностики некротизирующего энтероколита у новорожденных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |